Advances in Technology Applied in the Biotech Sector

Monday, January 30, 2017 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, January 30, 2017 /PRNewswire/ -- - One of the more interesting sectors

has been biotechnology. Advances made in various field and technologies have been pushing the sector to vigorously invest in new platforms and clinical trials. For example, advances in DNA sequencing technologies are decreasing prices of the procedure
and encourage R&D activities to better understand genetic variations and develop therapeutic solutions. According to a comprehensive report by Global Market Insights, the Biotechnology Market size was valued at over USD 330.3 billion in 2015 and will exceed USD 775.2 billion with 9.9% CAGR from 2016 to 2024. Mount Tam Biotechnologies, Inc. (OTC: MNTM), Anthera Pharmaceuticals (NASDAQ: ANTH), Protalix Biotherapeutics Inc. (NYSE: PLX), Novavax Inc. (NASDAQ: NVAX), Tenax Therapeutics Inc. (NASDAQ: TENX)

The research indicates that North America dominates, with revenue share in 2015 with over USD 137.4 billion owing to growing R&D initiatives by key industry players and rising awareness among public and private research institute. Europe biotechnology market share, along with APAC is projected to show growth during the coming years due to growing public health and introduction of healthcare benefits by government agencies in different countries.

Mount Tam Biotechnologies, Inc. (OTC: MNTM) is a developer and marketer of novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. The company's most advanced compound is being developed to treat systemic lupus erythematosus (SLE). Previously Mount Tam has partnered with the Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets involved are highly target specific polyketides - a class of compounds with a successful track record with the FDA drug approval process. Currently Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has completed non-GLP pre-clinical development.

On January 9th, Mount Tam announced that together with Cambridge, UK-based Isomerase Therapeutics Ltd, "have agreed to expand their research collaboration for the discovery and development of novel rapalogs in 2017. As part of this research collaboration, Mount Tam will work to characterize and advance discovery programs for a range of novel and proprietary rapalogs that have been developed through Isomerase's proprietary approach to improving microbial natural products via their unique biosynthetic medicinal chemistry platform."

The goal of the partnership is to discover and develop differentiated mTOR modulators that can improve upon currently marketed rapalogs. Richard Marshak, Mount Tam's CEO, said "We are excited by the opportunity to work with these novel rapalogs given the great potential for mTOR modulators to address a wide range of serious unmet medical needs across a range of therapeutic areas where satisfactory treatments are lacking. It is also rewarding to advance our collaboration with the team at Isomerase, one of the world's leaders in advancing microbial natural products".

Anthera Pharmaceuticals (NASDAQ: ANTH) is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development. Sollpura is Anthera's novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Blisibimod is Anthera's BAFF inhibitor for the potential treatment of IgA nephropathy.

Biopharmaceutical Company, Protalix Biotherapeutics Inc. (NYSE: PLX) is focused on the development, production and commercialization of recombinant therapeutic proteins produced by their proprietary ProCellEx® plant cell-based protein expression system. Protalix's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Its advanced clinical programs addresses Fabry disease, cystic fibrosis, and immune and inflammatory diseases. Further, Protalix conducts initial research to evaluate additional programs for developing proprietary proteins with improved clinical profiles exploiting the unique nature of plant cell expression.

Novavax Inc. (NASDAQ: NVAX) commenced initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults. The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine, with and without aluminum phosphate or Novavax` proprietary Matrix-M(TM) adjuvant, in older adults. The trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 300 older adults in the Southern Hemisphere. Participants are being enrolled and vaccinated outside of the RSV season to best assess immunogenicity. Top-line results are expected in the third quarter of 2017. "We believe that a more immunogenic vaccine in the older adult population should translate into a more efficacious vaccine," said Stanley C. Erck, President and CEO. "We expect the results from this trial to inform the next steps in our older adults program, and would ensure we maintain our leadership position in this very attractive market opportunity."

Tenax Therapeutics Inc. (NASDAQ: TENX) is a specialty pharmaceutical company focused on identifying, developing and commercializing products for critical care market. The Company owns North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Please Sign Up Now at to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only regurgitates financial or corporate news through our unique financial newswire and media platform. has been compensated three thousand dollars for financial news dissemination and pr services by a third party non affiliate for mount tam biotechnologies, inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: Media Contact: , +1-877-601-1879


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store